Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Operations (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Cash from Operations for 9 consecutive years, with 48700000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations changed N/A to 48700000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 46800000.0, a N/A change, with the full-year FY2025 number at 46800000.0, up 167.73% from a year prior.
  • Cash from Operations was 48700000.0 for Q4 2025 at Soleno Therapeutics, up from 43460000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 48700000.0 in Q4 2025 to a low of 32752000.0 in Q1 2025.